This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: D83.9 (common variable immunodeficiency, unspecified) | Special Copayment Reduction: V111 (rare disease, 10% copayment for 5 years after registration) |
| B. Synonyms | Common variable immunodeficiency NOS (CVID NOS), unspecified CVID, common variable hypogammaglobulinemia (unclassified type), Common variable hypogammaglobulinemia unspecified |
| C. Adult onset | Possibility of first onset in adulthood: high — CVID NOS is CVID without immunological subtype classification and is most commonly first diagnosed in adulthood (20s–40s) through recurrent infections; this is the group in which diagnostic delay is particularly prominent. |
| 1. History | Shares the overall history of CVID. D83.9 is a residual classification code assigned to CVID patients in whom no immunological subtype has been identified or who do not fit the classification criteria, and its meaning has gradually changed along with the history of CVID research. |
| 2. Causes | Single-gene cause not identified; polygenic predisposition presumed. Applies when immunological characteristics (B-cell numbers, autoantibodies, T-cell abnormalities) have not been assessed, or when after assessment the case does not fall under D83.0/D83.1/D83.2. Meeting the CVID diagnostic criteria is mandatory. |
| 3. Genetics | Genetically heterogeneous. To date, the causative gene is unidentified in most cases. Searching for causative variants with an NGS-based CVID panel or WES may allow reclassification to D83.0–D83.2 or another single-gene immunodeficiency. HLA associations are also involved. |
| 4. General epidemiology | Within the overall prevalence of CVID (1:25,000–1:50,000), the largest number of patients in actual clinical practice are registered under D83.9 as the group without immunological subtype classification. Diagnostic delay (on average 5–10 years) is most marked. Onset in adulthood at 20–35 years is most common. |
| 5. Pathophysiology | The common CVID mechanisms (impaired B-cell development, reduced class-switched memory B cells, poor plasma cell differentiation, various abnormalities of T-cell helper function) underlie it, but no specific immunological mechanism has been identified as predominant. |
| 6. Symptoms | Recurrent bacterial sinus and lung infections, bronchiectasis, gastrointestinal symptoms (diarrhea, malabsorption), autoimmune complications (variable frequency), increased risk of malignancy (lymphoma, gastric cancer). The entire symptom spectrum of D83.0–D83.2 may apply. |
| 7. Signs | IgG < 5 g/L + low IgA/IgM; poor vaccine response; variable B-cell fraction (normal to decreased); variable T-cell abnormalities (decreased CD4 in some); bronchiectasis (chest CT). |
| 8. Screening | Serum IgG/A/M measurement in adults with recurrent infections; post-vaccination antibody titers; complete blood count; chest CT when bronchiectasis is suspected. After a D83.9 diagnosis, B-cell/T-cell immunophenotyping for immunologic subtype reclassification. |
| 9. Diagnosis | D83.9 when standard CVID criteria (ESID 2016) are met + more specific classification as D83.0/D83.1/D83.2 is not possible. Additional testing and an NGS panel are recommended for immunologic subtype classification. |
| 10. Treatment | IgG replacement therapy (IVIG/SCIG) as the mainstay; prophylactic anti-infective therapy; additional treatment according to complications (following D83.0–D83.2 treatment principles). Targeted therapy introduced upon immunologic subtype reclassification. |
| 11. Prognosis | Long-term survival is generally possible under IVIG treatment. Main prognostic factors: extent of bronchiectasis at diagnosis, presence of autoimmune complications, development of malignancy. Unclassified subtype may worsen prognosis through missed opportunities for targeted therapy. |
| 12. Prevention | Live vaccines contraindicated; continued IVIG; subtype reclassification through regular immunologic reassessment; regular screening for pulmonary, gastrointestinal and malignant complications; promotion of early diagnosis (enhanced serum Ig screening in adults with recurrent infections). |
| 13. References | Bonilla FA et al. International Consensus Document (ICON): Common Variable Immunodeficiency Disorders … and 9 other papers |
D83.9 (common variable immunodeficiency, unspecified; CVID NOS) is a 'residual' classification code that arose in the historical development of CVID as a whole. It includes patients who meet the diagnostic criteria for CVID but are not clearly classified into any of the subtypes D83.0 (predominant abnormalities of B-cell numbers and function), D83.1 (predominant immunoregulatory T-cell disorders) or D83.2 (with autoantibodies to B or T cells), or in whom immunologic subtype evaluation has not been performed. The historical development of the CVID concept (1950s–70s), the establishment of diagnostic criteria (ESID/PAGID 1999, ESID/ICON revision 2016) and the development of B-cell immunophenotypic classification systems (Freiburg classification, EUROClass classification) shaped the clinical meaning of the D83.9 code.
Before the 1990s, most CVID patients were classified collectively as CVID without detailed immunologic subtype evaluation. Patients from this period are presumed to have mostly been registered under the D83.9 code after the introduction of ICD-10 (1990). From the 2000s onward, advances in flow cytometry and the introduction of B-cell immunophenotypic classification systems (Freiburg classification 2002, EUROClass 2008) made it possible to subdivide CVID according to B-cell numbers, the switched memory B-cell fraction, the proportion of CD21lo B cells and markers of T-cell abnormality. With these advances, many patients previously classified as D83.9 began to be reclassified into more precise subtypes.
From the 2010s onward, the clinical introduction of NGS (next-generation sequencing)-based immunodeficiency gene panels and whole-exome analysis identified single-gene causes (LRBA, CTLA4, NFKB1, PIK3CD, etc.) in some D83.9 patients, enabling more specific classification. Nevertheless, in actual clinical practice D83.9 remains the code under which the largest number of CVID patients are registered. This is because specialized testing for immunologic subtype classification is not performed in all clinical settings, and some patients do not fit existing subtype classification criteria even after detailed immunophenotypic evaluation.
CVID experts currently recommend attempting, whenever possible, to reclassify D83.9 patients into a more specific subtype or a monogenic immunodeficiency through additional immunologic and genetic evaluation. This is to open the possibility of targeted therapy (e.g., abatacept when LRBA/CTLA4 is identified, PI3K inhibitors for activating PIK3CD variants).
By definition, D83.9 meets the diagnostic criteria for CVID but no specific immunologic or genetic mechanism has been identified. Therefore, the common understanding of CVID as a whole is applied to its causes.
The underlying cause of CVID is an immunologic barrier that prevents B cells from differentiating into fully mature antibody-producing plasma cells. This barrier is attributable to one or more of ① intrinsic B-cell developmental defects (D83.0 mechanism), ② abnormal T-cell helper or regulatory function (D83.1 mechanism), ③ autoantibody-mediated lymphocyte destruction (D83.2 mechanism), or ④ mechanisms not yet identified. In D83.9 patients, none of these specific mechanisms is identified as predominant.
In most D83.9 patients no clear single-gene cause is identified, and polygenic predisposition is presumed to be the main basis of disease. Known monogenic causes of CVID (ICOS, TACI, BAFF-R, CD19, LRBA, CTLA4, NFKB1, NFKB2, PIK3CD, PIK3R1, etc.) are identified in about 10–20% of CVID patients, so the remaining 80–90% have polygenic or unidentified causes. Many of these patients are classified as D83.9.
Clinically, D83.9 patients share core clinical features such as recurrent infections and hypogammaglobulinemia with D83.0–D83.2 patients, but specific immunologic subtype markers (extreme loss of switched memory B cells, T-cell dysregulation, autoantibodies) are not prominent. The common causal basis of this heterogeneous group is presumed to involve a combination of impairment of the final stage of B-cell to plasma cell differentiation, insufficient T-cell help, or dysregulation of B-cell survival signals (BAFF, APRIL).
In terms of genetic basis, D83.9 is the most genetically heterogeneous CVID subtype. By definition, in most patients classified under this code no clear single-gene cause has been identified.
Excluding the cases of CVID with an identified single-gene cause (about 10–20%), the remaining patients belong to the polygenic group, which includes D83.9. Research to identify causes in these polygenically predisposed patients through genome-wide association studies (GWAS) and whole-exome sequencing (WES) is ongoing. Among the genetic association factors known to date, variants in the MHC (HLA) region, particularly the HLA-A1-B8-DR3-DQ2 haplotype, have been reported to be associated with CVID risk. This haplotype is also associated with IgA deficiency, supporting a shared genetic basis for CVID and IgA deficiency.
Combinations of non-synonymous single-nucleotide polymorphisms (non-synonymous SNPs) in immune-related genes—particularly the A181E variant of TACI (TNFRSF13B), polymorphisms of immunoglobulin heavy-chain constant region genes (IGHG or IGHM), and various cytokine and receptor gene polymorphisms—are presumed to contribute to polygenic predisposition to CVID. However, their individual contributions and combined effects have not yet been sufficiently elucidated.
When an NGS-based CVID gene panel (ICOS, TACI, BAFF-R, CD19, CD20, CD81, LRBA, CTLA4, NFKB1, NFKB2, PIK3CD, PIK3R1, ZNF341, CARD11, SEC61A1, etc.) or whole-exome analysis is performed in patients classified as D83.9, previously unidentified single-gene causes are found in some, allowing reclassification into a more specific subtype. Therefore, stepwise genetic testing in D83.9 patients is currently recommended to optimize treatment direction and for family counseling.
D83.9 (CVID NOS) is the code under which the largest number of CVID patients are registered in real-world clinical settings. This reflects the reality that specialized tests for immunologic subtype classification (B-cell immunophenotypic classification, Tfh/Treg quantification, autoantibody panels, etc.) are not routinely performed at all medical institutions, and that subtype classification itself has not been universally standardized. D83.9 is also used frequently in large databases such as the ESID registry.
Based on the overall prevalence of CVID (about 1:25,000–1:50,000), D83.9 is estimated to account for more than half of cases. The age-of-onset distribution is bimodal (teens + ages 20–35), and diagnostic delay (mean 5–10 years) is most pronounced in this subtype. The sex distribution is nearly equal. In Korea as well, most patients registered with CVID in Health Insurance Review & Assessment Service (HIRA) Special Copayment Reduction data are presumed to use the D83.9 code, suggesting the need to expand domestic specialized immunology infrastructure and strengthen subtype classification capacity.
The distribution of clinical complications in CVID NOS patients is similar to that of the overall CVID cohort. Bronchiectasis (25–50%), gastrointestinal complications (20–30%), autoimmune complications (20–25%) and malignancy (5–10%, especially non-Hodgkin lymphoma) are the main long-term complications. About 25–35% already have advanced bronchiectasis at diagnosis, a direct result of diagnostic delay. Several cohort studies have confirmed that early diagnosis and initiation of IVIG are key to delaying the progression of bronchiectasis.
The pathophysiology of D83.9 includes the common mechanisms of CVID, but it is a heterogeneous group in which no predominant subtype-specific mechanism has been identified. The core feature is failure of B cells to complete final differentiation into antibody-producing plasma cells, and the underlying mechanisms of this failure vary.
The reduction of class-switched memory B cells, a common immunologic abnormality of CVID, is also observed in most D83.9 patients. An insufficient germinal center reaction (lack of Tfh help or an intrinsic B-cell defect) impairs the formation of class-switched memory B cells, and the plasma cell and memory B-cell pools decrease, resulting in an overall reduction in IgG, IgA and IgM production. Antigen-specific antibody formation after vaccination is also insufficient.
In D83.9, subtype-specific mechanisms (autoantibody-mediated B-cell destruction, severe T-cell dysregulation) are not prominent, so the main mechanism in these patients is presumed to be functional impairment of the germinal center reaction. This may lie in reduced efficiency of the interaction between B cells and Tfh cells, or in the last step of plasma cell differentiation (abnormal activity of plasma cell differentiation transcription factors such as IRF4, BLIMP1 and XBP1). Such a mechanism is consistent with a pattern in which the efficiency of the overall germinal center reaction is reduced by polygenic predisposition rather than a single-gene abnormality.
Over the long term, hypogammaglobulinemia leads to a vicious cycle of impaired defense against encapsulated bacteria → recurrent pneumonia and sinusitis → cumulative lung parenchymal damage → bronchiectasis. Meanwhile, even if some patients have minor autoimmune phenomena (mild ITP, mild AIHA), they are classified as D83.9 if they do not meet D83.2 criteria or if no autoantibodies are detected. Even in these cases there is a long-term risk of progression of autoimmune complications, so continuous monitoring is necessary.
The clinical symptoms of D83.9 cover the typical phenotypic spectrum of CVID and include a variety of symptoms that do not clearly match any specific subtype among D83.0–D83.2.
Recurrent bacterial infections are the most characteristic and common symptom. Bacterial pneumonia two or more times per year, chronic or recurrent sinusitis, otitis media and bronchitis recur. Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis, Pseudomonas aeruginosa and others are the main causative organisms. As pneumonia recurs, lung parenchymal damage accumulates and bronchiectasis forms, leading to a vicious cycle of chronic airway infection and declining lung function. Chronic diarrhea and malabsorption due to Giardia lamblia infection are also important gastrointestinal complications.
Autoimmune complications occur in some patients. Autoimmune thrombocytopenia (ITP), autoimmune hemolytic anemia (AIHA), rheumatoid arthritis-like joint symptoms, autoimmune thyroid disease and others may occur. When such autoimmune complications develop in a D83.9 patient, whether D83.2 criteria are met should be reassessed and subtype reclassification considered.
Gastrointestinal complications: chronic diarrhea, malabsorption, enteric infections (Giardia, Cryptosporidium) and CVID enteropathy (small-intestinal villous atrophy, collagenous colitis) may occur. Malignancy: increased risk of non-Hodgkin lymphoma (7–10 times that of the general population), gastric cancer (H. pylori-related) and small-bowel cancer has been reported. Continuous surveillance for these malignancy risks is also needed in CVID NOS patients.
The physical and laboratory signs of D83.9 show common CVID findings, and the defining characteristic is the absence of prominent markers of a specific subtype.
Serum immunoglobulins: IgG < 5 g/L (or ≥2 SD below the age-specific mean) and reduced IgA and/or IgM are the key markers for CVID diagnosis. The degree of IgG reduction varies between patients, and in severe cases IgG may be below 1 g/L. Poor antigen-specific antibody response after vaccination is confirmed. Target antibody titers not reached when measured 4 weeks after pneumococcal or tetanus toxoid vaccination.
B-cell immunophenotype: the extreme loss of switched memory B cells seen in D83.0 may be absent, but varying degrees of reduction in switched memory B cells may be present. Total CD19+ B-cell count varies from normal to decreased. The proportion of CD21lo B cells (activated anergic B cells) is increased in some cases.
T-cell findings: severe CD4+ T-cell reduction or Tfh/Treg abnormalities as in D83.1 are not prominent, but mild CD4 reduction or a decreased CD4/CD8 ratio is observed in some patients. Physical findings: splenomegaly and (reactive) lymphadenopathy are possible; as bronchiectasis progresses, crackles on auscultation and an obstructive pattern on pulmonary function testing appear. Chest CT shows bronchiectasis, bronchial wall thickening and bronchiolitis.
The method of screening for D83.9 patients is the same as common CVID screening, after which additional evaluation for subtype classification is needed.
Serum Ig screening in adults with recurrent infections: serum IgG/A/M is measured in adults with two or more serious bacterial infections per year. In particular, serum Ig must be included when evaluating the cause of recurrent pneumonia, chronic sinusitis or bronchiectasis. This simple blood test is the starting point of CVID diagnosis. Serum Ig measurement is recommended when recurrent infections persist even after vaccination.
Confirmation that CVID diagnostic criteria are met: CVID is diagnosed after low IgG + low IgA/IgM + poor vaccine response + age 4 years or older + exclusion of secondary causes. Secondary causes (protein loss, nephrotic syndrome, malignancy, drugs) must be systematically excluded.
Additional screening for subtype classification: after CVID diagnosis is confirmed, flow cytometry (T/B/NK-cell fractions, switched memory B cells), T-cell function tests, autoantibody panels and Tfh/Treg quantification are performed for immunologic subtype classification. If the patient remains D83.9, an NGS-based CVID gene panel is additionally performed to search for a single-gene cause. Through this additional testing, patients may be reclassified as D83.0–D83.2 or as a more specific monogenic immunodeficiency.
The diagnosis of D83.9 consists of two conditions: meeting standard CVID criteria + inability to classify into a more specific subtype.
Standard CVID criteria (ESID 2016): ① IgG ≥2 SD below normal; ② reduced IgA and/or IgM; ③ poor response to vaccination (protein-conjugate or polysaccharide pneumococcal vaccine); ④ onset after age 4; ⑤ exclusion of secondary causes. When these 5 criteria are met, CVID is diagnosed, and if the immunologic features corresponding to D83.0/D83.1/D83.2 are not identified, it is classified as D83.9.
Additional tests for subtype classification: ① Flow cytometry: CD19+ B-cell count, switched memory B cells (CD27+IgD−IgM−), CD21lo B cells; Tfh (CD4+CXCR5+PD-1+), Treg (CD4+CD25+FoxP3+); activated T cells. ② Autoantibody panel: antiplatelet, DAT, ANA, anti-dsDNA, ANCA. ③ LRBA protein expression (flow cytometry). ④ NGS panel or WES. These tests are performed to assess whether criteria for D83.0–D83.2 or a monogenic immunodeficiency are met; if none apply, D83.9 is maintained.
Differentiation of secondary causes of CVID: secondary antibody deficiency due to protein-losing enteropathy (fecal alpha-1 antitrypsin), nephrotic syndrome (proteinuria, albumin), HIV infection, drugs (rituximab, steroids, anticonvulsants) and hematologic malignancies (chronic lymphocytic leukemia, lymphoma) is excluded.
Treatment of D83.9 follows the common principles of CVID treatment, and subtype-specific treatments are added after subtype reclassification.
IgG replacement therapy (IVIG/SCIG): the mainstay of treatment. Serum IgG is maintained at or above the target level (≥700–800 mg/dL) with IVIG every 3–4 weeks or subcutaneous SCIG 1–2 times per week. SCIG has advantages in patient convenience and maintenance of stable IgG levels, and can be self-administered. IgG replacement therapy plays a key role in reducing the frequency of bacterial infections and delaying the progression of bronchiectasis.
Infection management: prompt antibiotic treatment of acute bacterial infection episodes. With bronchiectasis, long-term prophylactic antibiotics (azithromycin three times weekly, doxycycline), mucolytics (N-acetylcysteine), postural drainage and pulmonary physiotherapy. Metronidazole or tinidazole when Giardia infection is confirmed.
Additional treatment when complications develop: when autoimmune cytopenia develops, D83.2 treatment principles (steroids, rituximab, abatacept) are applied. When granulomatous complications develop, D83.1 treatment principles (steroids, azathioprine) are applied. When malignant lymphoma develops, standard chemotherapy or HSCT is performed in collaboration with a hematologist-oncologist.
Targeted therapy after subtype reclassification: abatacept is introduced when NGS identifies an LRBA or CTLA4 variant. A PI3Kδ inhibitor (leniolisib) is considered when an activating PIK3CD variant (APDS) is identified. Regular genetic reassessment after diagnosis is important so as not to miss these targeted therapy opportunities.
The prognosis of D83.9 (CVID NOS) patients is generally similar to that of the overall CVID cohort, and long-term survival is possible with IgG replacement therapy. However, there are several important prognostic determinants.
The extent of bronchiectasis at diagnosis is the most important prognostic factor. If bronchiectasis has already progressed at diagnosis, the structural lung damage that has already occurred does not recover even after IVIG treatment is started, and chronic decline in lung function persists. This is a major cause of chronic morbidity in CVID. Therefore, minimizing diagnostic delay so that IVIG is started before bronchiectasis develops is decisive for long-term prognosis.
When autoimmune complications occur concomitantly, treatment becomes complicated and the adverse effects of long-term steroid use (increased infection risk, osteoporosis, diabetes) are added. When malignancy (non-Hodgkin lymphoma, gastric cancer) develops, prognosis is determined by the tumor type, stage and treatment response. Overall, if the immunologic subtype remains unclassified in D83.9 patients, the opportunity for targeted therapy may be lost and some patients may have a worse prognosis; regular immunologic and genetic reassessment is therefore emphasized.
Prevention for D83.9 follows the common prevention principles of CVID, with particular emphasis on early diagnosis and immunologic subtype reclassification.
Live vaccines absolutely contraindicated: all live vaccines, including measles-mumps-rubella (MMR), varicella, BCG, oral polio, yellow fever and nasal spray influenza, are contraindicated. Inactivated vaccines (pneumococcal, influenza, hepatitis B, tetanus) are recommended and may help reduce infection episodes even if the response is incomplete.
Continued IVIG/SCIG administration: continued without interruption to maintain serum IgG at or above the target level. IgG trough (immediately before dosing) levels are monitored at regular visits (every 3–6 months), and the dose or interval is adjusted if the target is not reached.
Regular immunologic reassessment and attempts at subtype reclassification: in D83.9 patients, immunophenotypic reassessment is performed within 1–2 years after diagnosis and whenever clinical changes occur (development of autoimmune complications, rapid B-cell decline, etc.), and a search for single-gene causes (CVID panel NGS, WES) is attempted to secure opportunities for targeted therapy.
Regular screening for pulmonary, malignant and autoimmune complications: pulmonary function tests and chest CT are performed every 6–12 months for early detection of bronchiectasis progression and pulmonary complications. LDH, blood counts and body weight (malignancy screening). Regular monitoring of autoantibodies and blood counts for early detection of autoimmune complications. Upper gastrointestinal endoscopy (H. pylori, gastric cancer) and colonoscopy (colon cancer) screening are performed at the recommended intervals.
Early diagnosis campaign: increasing awareness of serum Ig measurement in adults with recurrent bacterial infections (recurrent pneumonia and sinusitis) is key to reducing diagnostic delay in CVID NOS. Systems should be strengthened so that primary care physicians and internal medicine, otolaryngology and pulmonology physicians recognize the possibility of CVID and refer patients early to an immunologist.
Bonilla FA, Barlan I, Chapel H, et al. International Consensus Document (ICON): Common Variable Immunodeficiency Disorders. Journal of Allergy and Clinical Immunology: In Practice. 2016;4(1):38–59. DOI: 10.1016/j.jaip.2015.07.025. PMID: 26563668.
Cunningham-Rundles C. The many faces of common variable immunodeficiency. Hematology Am Soc Hematol Educ Program. 2012;2012:301–305. DOI: 10.1182/asheducation-2012.1.301. PMID: 23233597.
Chapel H, Lucas M, Lee M, et al. Common variable immunodeficiency disorders: division into distinct clinical phenotypes. Blood. 2008;112(2):277–286. DOI: 10.1182/blood-2007-11-124545. PMID: 18319398.
Wehr C, Kivioja T, Schmitt C, et al. The EUROclass trial: defining subgroups in common variable immunodeficiency. Blood. 2008;111(1):77–85. DOI: 10.1182/blood-2007-06-091744. PMID: 17898316.
Seidel MG, Kindle G, Gathmann B, et al. The ESID Registry Working Definitions for the Clinical Diagnosis of Inborn Errors of Immunity. Journal of Allergy and Clinical Immunology: In Practice. 2019;7(6):1763–1770. DOI: 10.1016/j.jaip.2019.02.004. PMID: 30776527.
Resnick ES, Moshier EL, Godbold JH, Cunningham-Rundles C. Morbidity and mortality in common variable immune deficiency over 4 decades. Blood. 2012;119(7):1650–1657. DOI: 10.1182/blood-2011-09-377945. PMID: 22180438.
Oksenhendler E, Gérard L, Fieschi C, et al. Infections in 252 patients with common variable immunodeficiency. Clinical Infectious Diseases. 2008;46(10):1547–1554. DOI: 10.1086/587669. PMID: 18419489.
Maglione PJ, Overbey JR, Radigan L, Bagiella E, Paul E, Cunningham-Rundles C. Pulmonary radiologic findings in common variable immunodeficiency: clinical and immunological correlations. Annals of Allergy, Asthma and Immunology. 2014;113(4):452–459. DOI: 10.1016/j.anai.2014.07.018. PMID: 25108455.
Salzer U, Grimbacher B. Common variable immunodeficiency: the power of co-stimulation. Seminars in Immunology. 2006;18(6):337–346. DOI: 10.1016/j.smim.2006.07.009. PMID: 17045808.
Picard C, Bobby Gaspar H, Al-Herz W, et al. International Union of Immunological Societies: 2017 Primary Immunodeficiency Diseases Committee Report on Inborn Errors of Immunity. Journal of Clinical Immunology. 2018;38(1):96–128. DOI: 10.1007/s10875-017-0464-9. PMID: 29226301.